Although direct inhibition of MCL1 may be associated with toxicities preventing clinical applications,14 the heterogeneous response to BH3‐mimetics observed in DLBCL necessitates the discovery of resistance mechanisms to BCL2i and predictive biomarkers to inform and guide clinical development. This evidence concerns the gene MCL1 and diffuse large B-cell lymphoma.